Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01093534 · ClinicalTrials.gov registry record · Phase 4
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
A Phase 4 study of Overactive Bladder and Detrusor Overactivity, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 547
- Enrollment target
- 20
- Study locations
NCT01093534 is a Phase 4 study of Overactive Bladder and Detrusor Overactivity that has completed, run by Astellas Pharma. The registered enrollment target is 547 participants, above the 199-participant average among 45 other Overactive Bladder trials with a reported enrollment target (175% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT01093534, a Phase 4 study of Overactive Bladder and Detrusor Overactivity, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 547 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose is to see if solifenacin has any effect on bladder wall thickness and urine inflammatory marker measurements after 12 weeks of treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG solifenacin
Study Locations (20)
Other
- - Graz
- - Linz
- - Linz
- - Edegem
- - Ghent
- - Kortrijk
- - Sofia
- - Sofia
- - Varba
Ontario
- - Barrie
- - Brampton
- - Brantford
- - Kitchener
- - Toronto
New York
- - New York
- - New York
British Columbia
- - Victoria
- - Victoria
Pennsylvania
- - West Reading
Quebec
- - Sherbrooke
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 547 participants |
| Start Date | 2010-01-19 |
| Est. Completion | 2011-06-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01093534
The ClinicalTrials.gov registry entry for NCT01093534 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 547 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 199-participant average among 45 other Overactive Bladder trials with a reported enrollment target (175% higher). The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Overactive Bladder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01093534 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Ontario, New York.
Frequently Asked Questions
What is clinical trial NCT01093534 about?
NCT01093534 is a clinical study titled "Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.". The purpose is to see if solifenacin has any effect on bladder wall thickness and urine inflammatory marker measurements after 12 weeks of treatment.
What is the current status of trial NCT01093534?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 547 participants. The study started on 2010-01-19. Estimated completion is 2011-06-23.
What conditions does trial NCT01093534 study?
This clinical trial studies the following conditions: Overactive Bladder, Detrusor Overactivity.
What interventions are being tested in trial NCT01093534?
The interventions under investigation include: Placebo (DRUG), solifenacin (DRUG).
Who is sponsoring clinical trial NCT01093534?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01093534 being conducted?
This trial has 20 study locations across New York, Pennsylvania, British Columbia, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bladder Botox UTI Antibiotic Prophylaxis
RECRUITING · Phase 4
-
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
RECRUITING · Phase 4
-
Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks
RECRUITING · Phase 4
-
TReating Incontinence for Underlying Mental and Physical Health
RECRUITING · Phase 4
-
Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder
COMPLETED · Phase 4
-
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.